drugset / Trial / NCT00088049

Study of Olanzapine vs. Aripiprazole in the Treatment of Schizophrenia

NCT00088049 ↗

Phase 4 Completed 560 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of the protocol is to evaluate the efficacy of olanzapine compared with Aripiprazole in patients with schizophrenia.

Timeline

Start
2003-10
Primary completion
—
Completion
2007-07

Outcome

Missed primary endpoint

paper Treatment groups did not differ significantly on the primary outcome. PMID 19323965 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Aripiprazole Other / unclassified — —
Subject Olanzapine Small molecule — —

Indications